Aims: LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products manufactured by distinct processes, but with identical amino acid sequences. This study compared the duration of action of LY IGlar and IGlar in subjects with type 1 diabetes mellitus (T1DM).
clamp studies in healthy subjects. 6 However, it is difficult to determine accurately the duration of action of exogenous insulin in healthy subjects because of the presence of endogenous insulin and the induction of hormonal responses during prolonged fasting.
This study was undertaken with the primary objective of comparing the duration of action of IGlar and LY IGlar in subjects with T1DM.
| MATERIALS AND METHODS

| Study subjects
The study protocol was approved by an ethical review board (Ärzte-kammer Nordrhein, Düsseldorf, Germany) and was conducted in accordance with the Declaration of Helsinki and good clinical practice guidelines. All subjects provided written informed consent prior to participating.
Male or female subjects ≥18 and ≤60 years of age with T1DM
were eligible for the study. Subjects were required to have had diabetes for ≥1 year, a body mass index ≤29 kg/m 2 , haemoglobin A1c (HbA1c) ≤86 mmol/mol (≤10.0%) and fasting C-peptide ≤ 0.3 nmol/ L. A summary of subject demographics and prior basal insulin therapy is provided in Table 1 .
| Study drugs
LY IGlar and IGlar were each supplied as a 100-U/mL solution in a cartridge and each product was from a single lot. A needle and syringe were used for the injections.
| Study design
This was a single-site, randomized, investigator-and subject-blind, single-dose, 2-period, crossover, 42-hour euglycaemic clamp study in subjects with T1DM (NCT01600950). When subjects were admitted to the study site, they were randomized to receive either 0.3 U/kg LY IGlar or 0.3 U/kg IGlar, followed by the other study drug in Period 2. Study personnel who performed the injections were unaware of the drug allocation. The use of standard insulin syringes ensured that there was no visual difference with regards to volume or appearance between the insulin products. The study design is illustrated in Figure 1 .
For each subject, the study consisted of a screening visit, two treatment periods separated by a washout period of seven to 21 days, and a follow-up visit 7-14 days after the last treatment. 
| Euglycaemic clamp procedures
After study drug administration, insulin lispro infusion (if any) was continued at a constant rate using the immediate postdose rate. The 
| Pharmacokinetics and bioanalytical methods
Venous blood collection for the determination of serum concentrations of IGlar and LY IGlar was initiated prior to and continued up to 42 hours after the administration of each insulin glargine. Serum samples were analysed for immunoreactive insulin glargine using a validated, competitive radioimmunoassay method at Covance Laboratories, Inc. (Chantilly, VA, USA) as described previously. 6 The lower limit of quantification was 50 pM and the upper limit was 2000 pM. The radioimmunoassay showed similar precision and accuracy in the measurement of immunoreactive insulin glargine against a standard curve prepared using Lantus ® (insulin glargine) as it did in the measurement of immunoreactive insulin glargine against a standard curve prepared using LY2963016. Serum samples were also analysed for insulin lispro using a validated radioimmunoassay with a lower limit of quantification of 0.200 ng/mL and an upper limit of 15.000 ng/mL (Covance Laboratories, Inc.).
| Pharmacodynamic analysis
The time profiles of glucose infusion rate (GIR) and blood glucose concentration were recorded during each clamp for each individual follow- 
| Pharmacodynamic statistical analysis
A time-to-event (survival) statistical analysis was conducted, allowing for censored observations. The duration of action was censored (i.e. not recorded) when a subject did not reach end of action before 42 hours. Each end of action was considered an "event". The survival curves were compared using the log-rank test of equality. In addition, the Cox proportional hazards regression, which included treatment and period as covariates, was fitted to the data. The Cox proportional hazards model 8 was used to estimate the hazard ratio; the corresponding 95% confidence intervals (CIs) and p-value (based on Wald test) were reported.
The PD parameters G tot and R max were log-transformed and analysed using a linear mixed-effects model in which treatment, period and sequence were considered fixed effects and subject was a random effect. The difference in least squares (LS) mean estimates and the corresponding 90% CIs for the difference between treatments were estimated and back-transformed from the log scale to provide estimates of the ratios of the geometric means and 90% CI for the ratio of these means. Other PD time parameters characterizing the time profile for GIR were evaluated using the same mixed-effects model but without transformation. The differences in means between the treatments and the associated 95% CIs for the differences were reported.
| Safety assessments
Safety assessments included physical examinations, clinical laboratory evaluations, and evaluations of vital signs, ECGs and adverse events (AEs). After screening to ensure that all study criteria were met, subjects were randomized to receive a single dose of 0.3 U/kg IGlar or 0.3 U/kg LY IGlar on day 1 of period 1, followed by a 42-hour euglycaemic clamp procedure. Following a washout period of 7-21 days, subjects received a single dose of the other insulin glargine on day 1 of period 2, followed by a 42-hour euglycaemic clamp procedure. Subjects returned for a follow-up visit 7-14 days after the second clamp procedure.
3 | RESULTS
| Demographics and baseline characteristics
Twenty male subjects with T1DM, aged 23-54 years, participated in and completed the study. Subject demographics, baseline diabetic characteristics and prior basal and total daily insulin dose are presented in Table 1 .
| Pharmacodynamics
Following single SC injections, the mean GIR profiles (Figure 2A ) and blood glucose levels ( Figure 2B (Table S1 ).
The mean difference in blood glucose from the target value (5.6 mmol/L) and the mean coefficient of variation of blood glucose levels were estimated to assess clamp quality. 
| Pharmacokinetics
Immunoreactive IGlar and LY IGlar were measured to determine insulin PK during the clamp procedure. Nine subjects had analysable PK data for both treatment periods, but insufficient concentration data were available for the remaining subjects, mainly because serum concentration levels were below the quantifiable lower limit (BQL) of the assay (50 pM) for either one or both treatment periods. Insulin lispro levels were detectable in only 18 of 280 serum samples across both clamp periods.
| Safety and tolerability
There were no notable differences in the incidence of treatment- 
| DISCUSSION
In the current study, the primary objective was to compare the dura- These studies were not conducted, however, with the intent to establish the interchangeability of LY IGlar and IGlar. Interchangeability requires a different scientific standard than biosimilarity, including a demonstration of safety for patients who are switched back and forth between the biosimilar and reference products. 12 The USA is unlike the EU and most other markets in that a decision regarding interchangeability is made by the US regulatory authority and can serve as a basis for a biosimilar to be substituted for the reference biological product at the pharmacy, and without advance notice or agreement of the prescriber. It remains to be seen whether pharmacy substitution of insulin products will be accepted by patients and providers, many of whom may be justifiably reluctant to permit substitution for a well-controlled patient or to support any such switch without medical supervision. 12 Because the previous LY IGlar PK/PD studies designed to meet bioequivalence criteria were conducted in healthy subjects, it has not been possible to compare the PD duration of action of LY IGlar and that of IGlar because of the presence of endogenous insulin. A higher dose of 0.5 U/kg and a clamp duration limited to 24 hours also contributed to preventing determination of the duration of action.
Regulatory guidelines recommend clamp durations of at least 24 hours for determining the duration of action of intermediate or long-acting insulins. 3 A clamp duration of 42 hours was used in the present study in an effort to allow a higher percentage of subjects to reach the end of action compared to shorter clamp durations. To our knowledge, this is the first euglycaemic clamp study reporting the duration of action for an insulin glargine using a clamp duration as long as 42 hours; although a clamp duration of 42 hours was also used in a study comparing IGlar and insulin degludec in subjects with T1DM, only data to 24 hours was reported. 13 While extending clamp duration further would allow for more subjects to reach end of action and potentially eliminate the need for right-censoring, practical considerations and safety concerns related to the length of fasting and the relatively high blood loss make it problematic to extend glucose clamps beyond 42 hours.
The 0.3-U/kg dose used here was similar to doses used in the previously reported Phase 3 trial in T1DM patients, in which the mean dose at 52 weeks was 0.36 U/kg/day for IGlar and 0.38 U/kg/ day for LY IGlar. 9 The dose of 0.3 U/kg was chosen so that the entire duration of action could be captured for the majority of subjects while maintaining a reasonable clamp duration. At the same time, the selected dose should, ideally, be high enough to allow for detection of the study drug by the bioanalytical assay. However, serum insulin levels were BQL (50 pM) following administration of the 0.3-U/kg dose of insulin glargine in many instances. Because less than half of the subjects had evaluable insulin PK profiles during both treatment periods and because there was considerable variability in the available data, definitive conclusions regarding insulin PK could not be T1DM patients [14] [15] [16] [17] [18] [19] and has also been recommended in regulatory guidance. 3 The idea of defining the duration of action in euglycaemic 2 The range and mean are based only on those subjects who reached end of action before 42 hours.
3 The Xth percentile of the duration of action is the time beyond which (100-X)% of the subjects have not reached the end of action.
4 Not applicable because of censoring. clamp studies using blood glucose rather than GIR is based on the concept that the main aim of basal insulin is to control blood glucose under fasting conditions. 16 While this approach can be useful, the data generated for basal insulins to this point indicate that the dura- Confirmation of clamp quality is an important consideration to ensure confidence in the results obtained in euglycaemic clamp studies. 7 In the current study, the mean difference between measured and target blood glucose levels was similarly low for both study insulins. The mean coefficient of variation of blood glucose levels was also similar between study insulins, with mean values of 6.3% and 6.5% for IGlar and LY IGlar, respectively.
Careful consideration was given to whether to conduct the study after a single dose or at steady state. Single-dose studies are more sensitive than steady-state studies for assessing PK and PD properties and can detect early differences in PD parameters that may not be apparent at steady state. Regulatory guidance 3,4 recommends single-dose studies as the default when comparing the PKs and PDs of a biosimilar and a reference product. Furthermore, data suggest that the PK of insulin glargine is linear in terms of time;
therefore, PK/PD after a single dose should predict PK/PD after multiple doses.
The ratios for the geometric LS means for G tot and R max were comparable between LY IGlar and IGlar. Other PD parameters characterizing the time profile for GIR (TR max , early TR max50%, late TR max50% )
were also comparable between LY IGlar and IGlar. While the current study was designed to compare the duration of action of LY IGlar and IGlar, the PD results are consistent with previous studies demonstrating that LY IGlar and IGlar met bioequivalence criteria with regard to the PD parameters G tot and R max at a dose of 0.5 U/kg. 6 In the present study, no safety concerns were noted in subjects with T1DM following administration of either LY IGlar or IGlar.
In summary, the results presented here demonstrate a similar duration of action for LY IGlar and IGlar in subjects with T1DM and also showed comparable PD parameters. In conjunction with previous studies demonstrating that LY IGlar PK/PD parameters met bioequivalence criteria in healthy subjects and clinical trials showing similar safety and efficacy in T1DM and T2DM subjects, the current study adds to the totality of evidence supporting the similarity of LY IGlar and IGlar.
